Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://thebagstore.nl
Are you over 18 and want to see adult content?
A complete backup of https://testingmom.com
Are you over 18 and want to see adult content?
A complete backup of https://jameswedmore.com
Are you over 18 and want to see adult content?
A complete backup of https://ngs1685.com
Are you over 18 and want to see adult content?
A complete backup of https://mireth.com
Are you over 18 and want to see adult content?
A complete backup of https://foxboroughma.gov
Are you over 18 and want to see adult content?
A complete backup of https://door2windows.com
Are you over 18 and want to see adult content?
A complete backup of https://patlive.com
Are you over 18 and want to see adult content?
A complete backup of https://yewknee.com
Are you over 18 and want to see adult content?
A complete backup of https://swissparks.info
Are you over 18 and want to see adult content?
A complete backup of https://toiyeubitcoin.com
Are you over 18 and want to see adult content?
A complete backup of https://metamusica.com.br
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://rivbike.com
Are you over 18 and want to see adult content?
A complete backup of https://cutm.ac.in
Are you over 18 and want to see adult content?
A complete backup of https://didar.store
Are you over 18 and want to see adult content?
A complete backup of https://autotransportcity.com
Are you over 18 and want to see adult content?
A complete backup of https://summitbrewing.com
Are you over 18 and want to see adult content?
A complete backup of https://unionbankonline.co.in
Are you over 18 and want to see adult content?
A complete backup of https://oxygenetix.com
Are you over 18 and want to see adult content?
A complete backup of https://magnaromagna.it
Are you over 18 and want to see adult content?
A complete backup of https://teisi.ru
Are you over 18 and want to see adult content?
A complete backup of https://iowamedicalmarijuana.org
Are you over 18 and want to see adult content?
A complete backup of https://happyfamilyorganics.com
Are you over 18 and want to see adult content?
A complete backup of https://dreamgold.es
Are you over 18 and want to see adult content?
Text
need it most.
TREATING SEVERE ACNE IN TRANSGENDER PATIENTS: AN UPDATE Dermatologists are increasingly seeing transgender patients with acne and other skin or cosmetic concerns. Transgender is the umbrella term for people whose gender identity differs from what they were thought to be at birth. As many as 1.4 million adults and 0.7 percent of youth aged 13 to 17 identify as transgender, according to the Williams NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC It’s time to update guidelines on screening for tuberculosis infection in patients being treated with biologics for psoriasis. In low-incidence TB regions such as the US, repeat latent TB infection testing in patients on biologic therapies should be focused on patients who have new risk factors for TB infection since their lastscreening. 1.
INVESTMENTS 101: CALCULATING CAPITAL EQUIPMENT PURCHASE While every physician and practice is different, Dr. Kaminer emphasizes a general rule of thumb regarding capital equipment purchases that may aid in early decision-making: “Aim to have the cost of a procedure (consumables plus device carrying costs) be lessthan 25 percent of
TAKING THE PULSE OF HYDROQUINONE THERAPY: A PLEA FOR Patient 4 (photo previous page) is a 57-year-old African-American female, seen 25 years ago for PIH and melasma. She responded well to a topical medication that included hydroquinone 4%, used daily, and hydroquinone mixed with retinoic acid in the evening. She also had a UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably WHY TELEHEALTH IS NEEDED AND WHY IT’S HERE TO STAY While its current form is modern, telehealth has technically been around since the 1950s. What is new, however, is the opportunity telehealth offers physicians and patients in these uncertain times. Telehealth visits will help to reduce transmission of the contagious coronavirus, while preserving PPE for healthcare professionals whoneed it most.
TREATING SEVERE ACNE IN TRANSGENDER PATIENTS: AN UPDATE Dermatologists are increasingly seeing transgender patients with acne and other skin or cosmetic concerns. Transgender is the umbrella term for people whose gender identity differs from what they were thought to be at birth. As many as 1.4 million adults and 0.7 percent of youth aged 13 to 17 identify as transgender, according to the Williams NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC It’s time to update guidelines on screening for tuberculosis infection in patients being treated with biologics for psoriasis. In low-incidence TB regions such as the US, repeat latent TB infection testing in patients on biologic therapies should be focused on patients who have new risk factors for TB infection since their lastscreening. 1.
INVESTMENTS 101: CALCULATING CAPITAL EQUIPMENT PURCHASE While every physician and practice is different, Dr. Kaminer emphasizes a general rule of thumb regarding capital equipment purchases that may aid in early decision-making: “Aim to have the cost of a procedure (consumables plus device carrying costs) be lessthan 25 percent of
TAKING THE PULSE OF HYDROQUINONE THERAPY: A PLEA FOR Patient 4 (photo previous page) is a 57-year-old African-American female, seen 25 years ago for PIH and melasma. She responded well to a topical medication that included hydroquinone 4%, used daily, and hydroquinone mixed with retinoic acid in the evening. She also had a UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and PRACTICAL DERMATOLOGY Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. TREATING PSORIASIS WITH FDA-APPROVED MEDICATIONS IN 2020 The purpose of this short paper is to provide a reference for all of the FDA-approved medications separated into topical treatments and systemic treatments in alphabetical order as well as their mechanisms of action, administrative advantages, indications, and side effects. The goal for the treatment of psoriasis is to eliminate symptoms ofthe
FDA APPROVES EXPANDED USE OF THE RECELL SYSTEM FOR The U.S. Food and Drug Administration (FDA) approved expanded use of the RECELL System in combination with meshed autografting for the treatment of all sizes of acute full-thickness thermal burn wounds for both pediatric and adult patients. MERZ AESTHETICS LAUNCHES NEW ONLINE AESTHETICS EDUCATION June 9, 2021 Merz Aesthetics Launches New Online Aesthetics Education Platform Established by Merz Aesthetics Global Medical Affairs, the Medical Forum provides on-demand content focused on medical aesthetics innovations and research to create more accessible scientificexchange.
EULAR: DAY SHOWN BENEFIT OF TREMFYA IN PSA AFTER ANTI-TNF New efficacy and safety data presented at the EULAR E-Congress suggest that first-in-class Tremfy (guselkumab) benefits adult patients with active PsA who had inadequate response or intolerance to TNF inhibitors. Tremfya is a selective IL-23 inhibitor from Janssen Pharmaceutical Companies of Johnson & Johnson.. In the COSMOS Phase 3b study, significantly higher proportions of patients treated CELLFX FROM PULSE BIOSCIENCES CLEARED IN CANADA The CellFX® System from Pulse Biosciences is now approved via a Medical Device License from Health Canada for use in dermatological procedures requiring ablation and resurfacing of the skin for the reduction, removal, and/or clearance of cellular-based benign lesions. ALLERGAN AESTHETICS, BOTOX COSMETIC UNVEIL ‘SEE YOURSELF Allergan Aesthetics is launching 'See Yourself', a new campaign featuring documentary-style shorts that tell the stories of real BotoxCosmetic patients.
FDA GRANTS BREAKTHROUGH DEVICE STATUS TO ALPHA DART FOR June 8, 2021 FDA Grants Breakthrough Device Status to Alpha DaRT for SCC The FDA granted Alpha Tau Medical a Breakthrough Device Designation for Alpha DaRT for the treatment of squamous cell carcinoma of the skin and oral cavity without curative standard ofcare.
SCIENTIFICALLY SPEAKING: NEW DIRECTIONS IN ACNE MANAGEMENT From the optimal, safe use of isotretinoin to the proper role for systemic antibiotics and beyond, there are multiple areas of systemic acne care that deserve attention. In the second of a 2-part series, host Joel L. Cohen, MD talks to Diane Berson, NURX ADDS ROSACEA CARE TO LIST OF SERVICES Nurx, now includes rosacea treatment in its at-home dermatology services. The service consists of a consultation with a Nurx medical provider, a personalized treatment plan for rosacea, home delivery of medication, and ongoing care. PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of WHY TELEHEALTH IS NEEDED AND WHY IT’S HERE TO STAY While its current form is modern, telehealth has technically been around since the 1950s. What is new, however, is the opportunity telehealth offers physicians and patients in these uncertain times. Telehealth visits will help to reduce transmission of the contagious coronavirus, while preserving PPE for healthcare professionals whoneed it most.
CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably TREATING SEVERE ACNE IN TRANSGENDER PATIENTS: AN UPDATE Dermatologists are increasingly seeing transgender patients with acne and other skin or cosmetic concerns. Transgender is the umbrella term for people whose gender identity differs from what they were thought to be at birth. As many as 1.4 million adults and 0.7 percent of youth aged 13 to 17 identify as transgender, according to the Williams DIET AND INFLAMMATION IN DERMATOLOGY The goal of an anti-inflammatory diet is to lower insulin production and subsequent visceral fat formation by avoiding high glycemic index foods. It is also recommended to avoid foods with pesticide exposure while eating fresh vegetables as a main source of carbohydrates andreducing the
UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC It’s time to update guidelines on screening for tuberculosis infection in patients being treated with biologics for psoriasis. In low-incidence TB regions such as the US, repeat latent TB infection testing in patients on biologic therapies should be focused on patients who have new risk factors for TB infection since their lastscreening. 1.
NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
INVESTMENTS 101: CALCULATING CAPITAL EQUIPMENT PURCHASE While every physician and practice is different, Dr. Kaminer emphasizes a general rule of thumb regarding capital equipment purchases that may aid in early decision-making: “Aim to have the cost of a procedure (consumables plus device carrying costs) be lessthan 25 percent of
UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of WHY TELEHEALTH IS NEEDED AND WHY IT’S HERE TO STAY While its current form is modern, telehealth has technically been around since the 1950s. What is new, however, is the opportunity telehealth offers physicians and patients in these uncertain times. Telehealth visits will help to reduce transmission of the contagious coronavirus, while preserving PPE for healthcare professionals whoneed it most.
CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably TREATING SEVERE ACNE IN TRANSGENDER PATIENTS: AN UPDATE Dermatologists are increasingly seeing transgender patients with acne and other skin or cosmetic concerns. Transgender is the umbrella term for people whose gender identity differs from what they were thought to be at birth. As many as 1.4 million adults and 0.7 percent of youth aged 13 to 17 identify as transgender, according to the Williams DIET AND INFLAMMATION IN DERMATOLOGY The goal of an anti-inflammatory diet is to lower insulin production and subsequent visceral fat formation by avoiding high glycemic index foods. It is also recommended to avoid foods with pesticide exposure while eating fresh vegetables as a main source of carbohydrates andreducing the
UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC It’s time to update guidelines on screening for tuberculosis infection in patients being treated with biologics for psoriasis. In low-incidence TB regions such as the US, repeat latent TB infection testing in patients on biologic therapies should be focused on patients who have new risk factors for TB infection since their lastscreening. 1.
NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
INVESTMENTS 101: CALCULATING CAPITAL EQUIPMENT PURCHASE While every physician and practice is different, Dr. Kaminer emphasizes a general rule of thumb regarding capital equipment purchases that may aid in early decision-making: “Aim to have the cost of a procedure (consumables plus device carrying costs) be lessthan 25 percent of
UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and PRACTICAL DERMATOLOGY Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. TREATING PSORIASIS WITH FDA-APPROVED MEDICATIONS IN 2020 The purpose of this short paper is to provide a reference for all of the FDA-approved medications separated into topical treatments and systemic treatments in alphabetical order as well as their mechanisms of action, administrative advantages, indications, and side effects. The goal for the treatment of psoriasis is to eliminate symptoms ofthe
FDA APPROVES EXPANDED USE OF THE RECELL SYSTEM FOR The U.S. Food and Drug Administration (FDA) approved expanded use of the RECELL System in combination with meshed autografting for the treatment of all sizes of acute full-thickness thermal burn wounds for both pediatric and adult patients. MERZ AESTHETICS LAUNCHES NEW ONLINE AESTHETICS EDUCATION June 9, 2021 Merz Aesthetics Launches New Online Aesthetics Education Platform Established by Merz Aesthetics Global Medical Affairs, the Medical Forum provides on-demand content focused on medical aesthetics innovations and research to create more accessible scientificexchange.
CELLFX FROM PULSE BIOSCIENCES CLEARED IN CANADA The CellFX® System from Pulse Biosciences is now approved via a Medical Device License from Health Canada for use in dermatological procedures requiring ablation and resurfacing of the skin for the reduction, removal, and/or clearance of cellular-based benign lesions. EULAR: DAY SHOWN BENEFIT OF TREMFYA IN PSA AFTER ANTI-TNF New efficacy and safety data presented at the EULAR E-Congress suggest that first-in-class Tremfy (guselkumab) benefits adult patients with active PsA who had inadequate response or intolerance to TNF inhibitors. Tremfya is a selective IL-23 inhibitor from Janssen Pharmaceutical Companies of Johnson & Johnson.. In the COSMOS Phase 3b study, significantly higher proportions of patients treated ALLERGAN AESTHETICS, BOTOX COSMETIC UNVEIL ‘SEE YOURSELF Allergan Aesthetics is launching 'See Yourself', a new campaign featuring documentary-style shorts that tell the stories of real BotoxCosmetic patients.
SCIENTIFICALLY SPEAKING: NEW DIRECTIONS IN ACNE MANAGEMENT From the optimal, safe use of isotretinoin to the proper role for systemic antibiotics and beyond, there are multiple areas of systemic acne care that deserve attention. In the second of a 2-part series, host Joel L. Cohen, MD talks to Diane Berson, FDA GRANTS BREAKTHROUGH DEVICE STATUS TO ALPHA DART FOR June 8, 2021 FDA Grants Breakthrough Device Status to Alpha DaRT for SCC The FDA granted Alpha Tau Medical a Breakthrough Device Designation for Alpha DaRT for the treatment of squamous cell carcinoma of the skin and oral cavity without curative standard ofcare.
NURX ADDS ROSACEA CARE TO LIST OF SERVICES Nurx, now includes rosacea treatment in its at-home dermatology services. The service consists of a consultation with a Nurx medical provider, a personalized treatment plan for rosacea, home delivery of medication, and ongoing care. PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
TREATING SEVERE ACNE IN TRANSGENDER PATIENTS: AN UPDATE Dermatologists are increasingly seeing transgender patients with acne and other skin or cosmetic concerns. Transgender is the umbrella term for people whose gender identity differs from what they were thought to be at birth. As many as 1.4 million adults and 0.7 percent of youth aged 13 to 17 identify as transgender, according to the Williams CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably TREATING PSORIASIS WITH FDA-APPROVED MEDICATIONS IN 2020 The purpose of this short paper is to provide a reference for all of the FDA-approved medications separated into topical treatments and systemic treatments in alphabetical order as well as their mechanisms of action, administrative advantages, indications, and side effects. The goal for the treatment of psoriasis is to eliminate symptoms ofthe
UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC It’s time to update guidelines on screening for tuberculosis infection in patients being treated with biologics for psoriasis. In low-incidence TB regions such as the US, repeat latent TB infection testing in patients on biologic therapies should be focused on patients who have new risk factors for TB infection since their lastscreening. 1.
NATROBA NOW APPROVED FOR SCABIES IN ADULTS AND CHILDREN AS Natroba™ (spinosad) Topical Suspension, 0.9% is now approved as a topical treatment for scabies infestations in adult and pediatric patients four years of age and older. ParaPRO received approval of a supplemental New Drug Application (sNDA) for Natroba™, which has been approved for the topical treatment of head lice infestations since 2011. It is currently the most frequently prescribed OPTIMIZING ISOTRETINOIN TREATMENT: KEYS TO SUCCESSFUL Isotretinoin, the drug that revolutionized acne treatment, is the only medication that can clear acne and produce long-term remissions. Since its introduction in 1982, it continues to be a vital and widely used acne medication worldwide. UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
TREATING SEVERE ACNE IN TRANSGENDER PATIENTS: AN UPDATE Dermatologists are increasingly seeing transgender patients with acne and other skin or cosmetic concerns. Transgender is the umbrella term for people whose gender identity differs from what they were thought to be at birth. As many as 1.4 million adults and 0.7 percent of youth aged 13 to 17 identify as transgender, according to the Williams CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably TREATING PSORIASIS WITH FDA-APPROVED MEDICATIONS IN 2020 The purpose of this short paper is to provide a reference for all of the FDA-approved medications separated into topical treatments and systemic treatments in alphabetical order as well as their mechanisms of action, administrative advantages, indications, and side effects. The goal for the treatment of psoriasis is to eliminate symptoms ofthe
UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC It’s time to update guidelines on screening for tuberculosis infection in patients being treated with biologics for psoriasis. In low-incidence TB regions such as the US, repeat latent TB infection testing in patients on biologic therapies should be focused on patients who have new risk factors for TB infection since their lastscreening. 1.
NATROBA NOW APPROVED FOR SCABIES IN ADULTS AND CHILDREN AS Natroba™ (spinosad) Topical Suspension, 0.9% is now approved as a topical treatment for scabies infestations in adult and pediatric patients four years of age and older. ParaPRO received approval of a supplemental New Drug Application (sNDA) for Natroba™, which has been approved for the topical treatment of head lice infestations since 2011. It is currently the most frequently prescribed OPTIMIZING ISOTRETINOIN TREATMENT: KEYS TO SUCCESSFUL Isotretinoin, the drug that revolutionized acne treatment, is the only medication that can clear acne and produce long-term remissions. Since its introduction in 1982, it continues to be a vital and widely used acne medication worldwide. UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and PRACTICAL DERMATOLOGY Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. FDA APPROVES EXPANDED USE OF THE RECELL SYSTEM FOR The U.S. Food and Drug Administration (FDA) approved expanded use of the RECELL System in combination with meshed autografting for the treatment of all sizes of acute full-thickness thermal burn wounds for both pediatric and adult patients. MERZ AESTHETICS LAUNCHES NEW ONLINE AESTHETICS EDUCATION June 9, 2021 Merz Aesthetics Launches New Online Aesthetics Education Platform Established by Merz Aesthetics Global Medical Affairs, the Medical Forum provides on-demand content focused on medical aesthetics innovations and research to create more accessible scientificexchange.
CELLFX FROM PULSE BIOSCIENCES CLEARED IN CANADA The CellFX® System from Pulse Biosciences is now approved via a Medical Device License from Health Canada for use in dermatological procedures requiring ablation and resurfacing of the skin for the reduction, removal, and/or clearance of cellular-based benign lesions. SKINSAFE, CVS NAME TOP 25 2021 SUNSCREEN AWARD WINNERS FOR June 7, 2021 SkinSAFE, CVS Name Top 25 2021 Sunscreen Award Winners for Sensitive Skin Developed in collaboration with Mayo Clinic, SkinSAFE helps people with sensitive skin find products that meet their sensitive skin needs, and to avoid products that may contain potential irritants. FDA GRANTS BREAKTHROUGH DEVICE STATUS TO ALPHA DART FOR June 8, 2021 FDA Grants Breakthrough Device Status to Alpha DaRT for SCC The FDA granted Alpha Tau Medical a Breakthrough Device Designation for Alpha DaRT for the treatment of squamous cell carcinoma of the skin and oral cavity without curative standard ofcare.
ALLERGAN AESTHETICS, BOTOX COSMETIC UNVEIL ‘SEE YOURSELF Allergan Aesthetics is launching 'See Yourself', a new campaign featuring documentary-style shorts that tell the stories of real BotoxCosmetic patients.
EULAR: DAY SHOWN BENEFIT OF TREMFYA IN PSA AFTER ANTI-TNF New efficacy and safety data presented at the EULAR E-Congress suggest that first-in-class Tremfy (guselkumab) benefits adult patients with active PsA who had inadequate response or intolerance to TNF inhibitors. Tremfya is a selective IL-23 inhibitor from Janssen Pharmaceutical Companies of Johnson & Johnson.. In the COSMOS Phase 3b study, significantly higher proportions of patients treated SCIENTIFICALLY SPEAKING: NEW DIRECTIONS IN ACNE MANAGEMENT From the optimal, safe use of isotretinoin to the proper role for systemic antibiotics and beyond, there are multiple areas of systemic acne care that deserve attention. In the second of a 2-part series, host Joel L. Cohen, MD talks to Diane Berson, NURX ADDS ROSACEA CARE TO LIST OF SERVICES Nurx, now includes rosacea treatment in its at-home dermatology services. The service consists of a consultation with a Nurx medical provider, a personalized treatment plan for rosacea, home delivery of medication, and ongoing care. PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably TREATING PSORIASIS WITH FDA-APPROVED MEDICATIONS IN 2020 The purpose of this short paper is to provide a reference for all of the FDA-approved medications separated into topical treatments and systemic treatments in alphabetical order as well as their mechanisms of action, administrative advantages, indications, and side effects. The goal for the treatment of psoriasis is to eliminate symptoms ofthe
TREATING SEVERE ACNE IN TRANSGENDER PATIENTS: AN UPDATE Dermatologists are increasingly seeing transgender patients with acne and other skin or cosmetic concerns. Transgender is the umbrella term for people whose gender identity differs from what they were thought to be at birth. As many as 1.4 million adults and 0.7 percent of youth aged 13 to 17 identify as transgender, according to the Williams UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC It’s time to update guidelines on screening for tuberculosis infection in patients being treated with biologics for psoriasis. In low-incidence TB regions such as the US, repeat latent TB infection testing in patients on biologic therapies should be focused on patients who have new risk factors for TB infection since their lastscreening. 1.
NATROBA NOW APPROVED FOR SCABIES IN ADULTS AND CHILDREN AS Natroba™ (spinosad) Topical Suspension, 0.9% is now approved as a topical treatment for scabies infestations in adult and pediatric patients four years of age and older. ParaPRO received approval of a supplemental New Drug Application (sNDA) for Natroba™, which has been approved for the topical treatment of head lice infestations since 2011. It is currently the most frequently prescribed TAKING THE PULSE OF HYDROQUINONE THERAPY: A PLEA FOR Patient 4 (photo previous page) is a 57-year-old African-American female, seen 25 years ago for PIH and melasma. She responded well to a topical medication that included hydroquinone 4%, used daily, and hydroquinone mixed with retinoic acid in the evening. She also had a UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably TREATING PSORIASIS WITH FDA-APPROVED MEDICATIONS IN 2020 The purpose of this short paper is to provide a reference for all of the FDA-approved medications separated into topical treatments and systemic treatments in alphabetical order as well as their mechanisms of action, administrative advantages, indications, and side effects. The goal for the treatment of psoriasis is to eliminate symptoms ofthe
TREATING SEVERE ACNE IN TRANSGENDER PATIENTS: AN UPDATE Dermatologists are increasingly seeing transgender patients with acne and other skin or cosmetic concerns. Transgender is the umbrella term for people whose gender identity differs from what they were thought to be at birth. As many as 1.4 million adults and 0.7 percent of youth aged 13 to 17 identify as transgender, according to the Williams UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC It’s time to update guidelines on screening for tuberculosis infection in patients being treated with biologics for psoriasis. In low-incidence TB regions such as the US, repeat latent TB infection testing in patients on biologic therapies should be focused on patients who have new risk factors for TB infection since their lastscreening. 1.
NATROBA NOW APPROVED FOR SCABIES IN ADULTS AND CHILDREN AS Natroba™ (spinosad) Topical Suspension, 0.9% is now approved as a topical treatment for scabies infestations in adult and pediatric patients four years of age and older. ParaPRO received approval of a supplemental New Drug Application (sNDA) for Natroba™, which has been approved for the topical treatment of head lice infestations since 2011. It is currently the most frequently prescribed TAKING THE PULSE OF HYDROQUINONE THERAPY: A PLEA FOR Patient 4 (photo previous page) is a 57-year-old African-American female, seen 25 years ago for PIH and melasma. She responded well to a topical medication that included hydroquinone 4%, used daily, and hydroquinone mixed with retinoic acid in the evening. She also had a UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and VITILIGO: ORAL AND TOPICAL JAKS SHOW PROMISE The JAK 1/3 inhibitor tofacitinib (Xeljanz, Pfizer) was FDA approved in 2012 for the treatment of moderate to severe rheumatoid arthritis and then later also approved for psoriatic arthritis. Oral and topical formulations have demonstrated safety and efficacy for the treatment of plaque psoriasis and oral tofacitinib for treating alopecia. MERZ AESTHETICS LAUNCHES NEW ONLINE AESTHETICS EDUCATION June 9, 2021 Merz Aesthetics Launches New Online Aesthetics Education Platform Established by Merz Aesthetics Global Medical Affairs, the Medical Forum provides on-demand content focused on medical aesthetics innovations and research to create more accessible scientificexchange.
FDA APPROVES EXPANDED USE OF THE RECELL SYSTEM FOR The U.S. Food and Drug Administration (FDA) approved expanded use of the RECELL System in combination with meshed autografting for the treatment of all sizes of acute full-thickness thermal burn wounds for both pediatric and adult patients. EULAR: DAY SHOWN BENEFIT OF TREMFYA IN PSA AFTER ANTI-TNF New efficacy and safety data presented at the EULAR E-Congress suggest that first-in-class Tremfy (guselkumab) benefits adult patients with active PsA who had inadequate response or intolerance to TNF inhibitors. Tremfya is a selective IL-23 inhibitor from Janssen Pharmaceutical Companies of Johnson & Johnson.. In the COSMOS Phase 3b study, significantly higher proportions of patients treated SKINSAFE, CVS NAME TOP 25 2021 SUNSCREEN AWARD WINNERS FOR June 7, 2021 SkinSAFE, CVS Name Top 25 2021 Sunscreen Award Winners for Sensitive Skin Developed in collaboration with Mayo Clinic, SkinSAFE helps people with sensitive skin find products that meet their sensitive skin needs, and to avoid products that may contain potential irritants. CELLFX FROM PULSE BIOSCIENCES CLEARED IN CANADA The CellFX® System from Pulse Biosciences is now approved via a Medical Device License from Health Canada for use in dermatological procedures requiring ablation and resurfacing of the skin for the reduction, removal, and/or clearance of cellular-based benign lesions. OPTIMIZING ISOTRETINOIN TREATMENT: KEYS TO SUCCESSFUL Isotretinoin, the drug that revolutionized acne treatment, is the only medication that can clear acne and produce long-term remissions. Since its introduction in 1982, it continues to be a vital and widely used acne medication worldwide. ALLERGAN AESTHETICS, BOTOX COSMETIC UNVEIL ‘SEE YOURSELF Allergan Aesthetics is launching 'See Yourself', a new campaign featuring documentary-style shorts that tell the stories of real BotoxCosmetic patients.
SCIENTIFICALLY SPEAKING: NEW DIRECTIONS IN ACNE MANAGEMENT From the optimal, safe use of isotretinoin to the proper role for systemic antibiotics and beyond, there are multiple areas of systemic acne care that deserve attention. In the second of a 2-part series, host Joel L. Cohen, MD talks to Diane Berson, FDA GRANTS BREAKTHROUGH DEVICE STATUS TO ALPHA DART FOR June 8, 2021 FDA Grants Breakthrough Device Status to Alpha DaRT for SCC The FDA granted Alpha Tau Medical a Breakthrough Device Designation for Alpha DaRT for the treatment of squamous cell carcinoma of the skin and oral cavity without curative standard ofcare.
PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably EXPLORING THE CONNECTION BETWEEN GUT HEALTH AND HAIR The Gut/Hair Connection. Evolving indicators suggest a connection between gut health and hair growth that remains to be proven. For example, when two refractory alopecia universalis patients underwent fecal-matter transplant (FMT) for recurrent Clostridium difficile infection (CDI), they experienced subsequent hair regrowth.This suggests gut flora composition may be associated with immune NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
OPTIMIZING ISOTRETINOIN TREATMENT: KEYS TO SUCCESSFUL Isotretinoin, the drug that revolutionized acne treatment, is the only medication that can clear acne and produce long-term remissions. Since its introduction in 1982, it continues to be a vital and widely used acne medication worldwide. TAKING THE PULSE OF HYDROQUINONE THERAPY: A PLEA FOR Patient 4 (photo previous page) is a 57-year-old African-American female, seen 25 years ago for PIH and melasma. She responded well to a topical medication that included hydroquinone 4%, used daily, and hydroquinone mixed with retinoic acid in the evening. She also had a UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and TNF INHIBITORS AND THE RISK OF MELANOMA ONCOLOGY ATC AuGusT 2013 PRACTICAL DERMATOLOGY 47 Other studies have reached similar conclusions.7,8 However, the incidence of non-melanoma skin cancer has been NEW INSIGHTS INTO AZELAIC ACID CLINIC FOC ACNE/ROSACEA 46 PracTIcaL DErmaTOLOGY march 2013 improved for this indication, azelaic acid is commonly used off-label to treatpigmentation.
PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably EXPLORING THE CONNECTION BETWEEN GUT HEALTH AND HAIR The Gut/Hair Connection. Evolving indicators suggest a connection between gut health and hair growth that remains to be proven. For example, when two refractory alopecia universalis patients underwent fecal-matter transplant (FMT) for recurrent Clostridium difficile infection (CDI), they experienced subsequent hair regrowth.This suggests gut flora composition may be associated with immune NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
OPTIMIZING ISOTRETINOIN TREATMENT: KEYS TO SUCCESSFUL Isotretinoin, the drug that revolutionized acne treatment, is the only medication that can clear acne and produce long-term remissions. Since its introduction in 1982, it continues to be a vital and widely used acne medication worldwide. TAKING THE PULSE OF HYDROQUINONE THERAPY: A PLEA FOR Patient 4 (photo previous page) is a 57-year-old African-American female, seen 25 years ago for PIH and melasma. She responded well to a topical medication that included hydroquinone 4%, used daily, and hydroquinone mixed with retinoic acid in the evening. She also had a UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and TNF INHIBITORS AND THE RISK OF MELANOMA ONCOLOGY ATC AuGusT 2013 PRACTICAL DERMATOLOGY 47 Other studies have reached similar conclusions.7,8 However, the incidence of non-melanoma skin cancer has been NEW INSIGHTS INTO AZELAIC ACID CLINIC FOC ACNE/ROSACEA 46 PracTIcaL DErmaTOLOGY march 2013 improved for this indication, azelaic acid is commonly used off-label to treatpigmentation.
NEW RESEARCH SHOWS HOW IMMUNE CELLS ORGANIZE THEMSELVES IN New research reveals how the skin’s immune cells organize themselves to ward off would-be intruders. Skin’s immune cells have a history of being misunderstood. SKINSAFE, CVS NAME TOP 25 2021 SUNSCREEN AWARD WINNERS FOR June 7, 2021 SkinSAFE, CVS Name Top 25 2021 Sunscreen Award Winners for Sensitive Skin Developed in collaboration with Mayo Clinic, SkinSAFE helps people with sensitive skin find products that meet their sensitive skin needs, and to avoid products that may contain potential irritants. NPF COVID-19 TASK FORCE: MASKS, SOCIAL DISTANCING STILL NPF recommends that patients with psoriatic disease taking abatacept, cyclosporine, leflunomide, glucocorticoids (e.g., prednisone), methotrexate, or tofacitinib continue masking and social distancing precautions when they are in contact with people not ALLERGAN AESTHETICS, BOTOX COSMETIC UNVEIL ‘SEE YOURSELF Allergan Aesthetics is launching 'See Yourself', a new campaign featuring documentary-style shorts that tell the stories of real BotoxCosmetic patients.
SKIN OF COLOR UPDATE GOES VIRTUAL FOR 2020 Skin of Color Update’s 2020 event is going virtual. The largest medical education event focused on the dermatologic treatment of skin of color will be held September 12-13. The Skin of Color Update agenda has been modified to reflect virtual learning. Live sessions, Q&A, poster sessions and panel discussions are included in the program. UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC It’s time to update guidelines on screening for tuberculosis infection in patients being treated with biologics for psoriasis. In low-incidence TB regions such as the US, repeat latent TB infection testing in patients on biologic therapies should be focused on patients who have new risk factors for TB infection since their lastscreening. 1.
DIET AND INFLAMMATION IN DERMATOLOGY The goal of an anti-inflammatory diet is to lower insulin production and subsequent visceral fat formation by avoiding high glycemic index foods. It is also recommended to avoid foods with pesticide exposure while eating fresh vegetables as a main source of carbohydrates andreducing the
FDA GRANTS BREAKTHROUGH DEVICE STATUS TO ALPHA DART FOR June 8, 2021 FDA Grants Breakthrough Device Status to Alpha DaRT for SCC The FDA granted Alpha Tau Medical a Breakthrough Device Designation for Alpha DaRT for the treatment of squamous cell carcinoma of the skin and oral cavity without curative standard ofcare.
THE PA SALARY: STRUCTURES AND STRATEGIES The PA would receive a base salary of $80,000 per year. In addition, the PA would be paid 20 percent of her collected revenue, after deducting $160,000 (double her base salary) from the total collected revenue. Assume her total collections are $350K: $350K - $160K = $190K. Twenty percent of $190K is $38,000. For that fiscal year, thatPA would
DERMAVANT SUBMITS NDA FOR TAPINAROF FOR PSO Dermavant Sciences has submitted a New Drug Application (NDA) to the FDA for tapinarof for the treatment of mild, moderate, and severeplaque psoriasi
PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably EXPLORING THE CONNECTION BETWEEN GUT HEALTH AND HAIR The Gut/Hair Connection. Evolving indicators suggest a connection between gut health and hair growth that remains to be proven. For example, when two refractory alopecia universalis patients underwent fecal-matter transplant (FMT) for recurrent Clostridium difficile infection (CDI), they experienced subsequent hair regrowth.This suggests gut flora composition may be associated with immune NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
OPTIMIZING ISOTRETINOIN TREATMENT: KEYS TO SUCCESSFUL Isotretinoin, the drug that revolutionized acne treatment, is the only medication that can clear acne and produce long-term remissions. Since its introduction in 1982, it continues to be a vital and widely used acne medication worldwide. TAKING THE PULSE OF HYDROQUINONE THERAPY: A PLEA FOR Patient 4 (photo previous page) is a 57-year-old African-American female, seen 25 years ago for PIH and melasma. She responded well to a topical medication that included hydroquinone 4%, used daily, and hydroquinone mixed with retinoic acid in the evening. She also had a UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and TNF INHIBITORS AND THE RISK OF MELANOMA ONCOLOGY ATC AuGusT 2013 PRACTICAL DERMATOLOGY 47 Other studies have reached similar conclusions.7,8 However, the incidence of non-melanoma skin cancer has been NEW INSIGHTS INTO AZELAIC ACID CLINIC FOC ACNE/ROSACEA 46 PracTIcaL DErmaTOLOGY march 2013 improved for this indication, azelaic acid is commonly used off-label to treatpigmentation.
PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably EXPLORING THE CONNECTION BETWEEN GUT HEALTH AND HAIR The Gut/Hair Connection. Evolving indicators suggest a connection between gut health and hair growth that remains to be proven. For example, when two refractory alopecia universalis patients underwent fecal-matter transplant (FMT) for recurrent Clostridium difficile infection (CDI), they experienced subsequent hair regrowth.This suggests gut flora composition may be associated with immune NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC It continues to be a first-line treatment. The histology of both SKs and verrucae is primarily epidermal, and thus it is not surprising that 5-FU 2.5%/salicylic acid 17% works well for these lesions as well. We have had success using 5-FU 2.5%/salicylic acid 17% as aguided
OPTIMIZING ISOTRETINOIN TREATMENT: KEYS TO SUCCESSFUL Isotretinoin, the drug that revolutionized acne treatment, is the only medication that can clear acne and produce long-term remissions. Since its introduction in 1982, it continues to be a vital and widely used acne medication worldwide. TAKING THE PULSE OF HYDROQUINONE THERAPY: A PLEA FOR Patient 4 (photo previous page) is a 57-year-old African-American female, seen 25 years ago for PIH and melasma. She responded well to a topical medication that included hydroquinone 4%, used daily, and hydroquinone mixed with retinoic acid in the evening. She also had a UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and TNF INHIBITORS AND THE RISK OF MELANOMA ONCOLOGY ATC AuGusT 2013 PRACTICAL DERMATOLOGY 47 Other studies have reached similar conclusions.7,8 However, the incidence of non-melanoma skin cancer has been NEW INSIGHTS INTO AZELAIC ACID CLINIC FOC ACNE/ROSACEA 46 PracTIcaL DErmaTOLOGY march 2013 improved for this indication, azelaic acid is commonly used off-label to treatpigmentation.
NEW RESEARCH SHOWS HOW IMMUNE CELLS ORGANIZE THEMSELVES IN New research reveals how the skin’s immune cells organize themselves to ward off would-be intruders. Skin’s immune cells have a history of being misunderstood. SKINSAFE, CVS NAME TOP 25 2021 SUNSCREEN AWARD WINNERS FOR June 7, 2021 SkinSAFE, CVS Name Top 25 2021 Sunscreen Award Winners for Sensitive Skin Developed in collaboration with Mayo Clinic, SkinSAFE helps people with sensitive skin find products that meet their sensitive skin needs, and to avoid products that may contain potential irritants. SKIN OF COLOR UPDATE GOES VIRTUAL FOR 2020 Skin of Color Update’s 2020 event is going virtual. The largest medical education event focused on the dermatologic treatment of skin of color will be held September 12-13. The Skin of Color Update agenda has been modified to reflect virtual learning. Live sessions, Q&A, poster sessions and panel discussions are included in the program. TREATING SEVERE ACNE IN TRANSGENDER PATIENTS: AN UPDATE Dermatologists are increasingly seeing transgender patients with acne and other skin or cosmetic concerns. Transgender is the umbrella term for people whose gender identity differs from what they were thought to be at birth. As many as 1.4 million adults and 0.7 percent of youth aged 13 to 17 identify as transgender, according to the Williams UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC It’s time to update guidelines on screening for tuberculosis infection in patients being treated with biologics for psoriasis. In low-incidence TB regions such as the US, repeat latent TB infection testing in patients on biologic therapies should be focused on patients who have new risk factors for TB infection since their lastscreening. 1.
DIET AND INFLAMMATION IN DERMATOLOGY The goal of an anti-inflammatory diet is to lower insulin production and subsequent visceral fat formation by avoiding high glycemic index foods. It is also recommended to avoid foods with pesticide exposure while eating fresh vegetables as a main source of carbohydrates andreducing the
NPF COVID-19 TASK FORCE: MASKS, SOCIAL DISTANCING STILL NPF recommends that patients with psoriatic disease taking abatacept, cyclosporine, leflunomide, glucocorticoids (e.g., prednisone), methotrexate, or tofacitinib continue masking and social distancing precautions when they are in contact with people not THE PA SALARY: STRUCTURES AND STRATEGIES The PA would receive a base salary of $80,000 per year. In addition, the PA would be paid 20 percent of her collected revenue, after deducting $160,000 (double her base salary) from the total collected revenue. Assume her total collections are $350K: $350K - $160K = $190K. Twenty percent of $190K is $38,000. For that fiscal year, thatPA would
DERMAVANT SUBMITS NDA FOR TAPINAROF FOR PSO Dermavant Sciences has submitted a New Drug Application (NDA) to the FDA for tapinarof for the treatment of mild, moderate, and severeplaque psoriasi
WHAT WAS YOUR FAVORITE TRIP AS A CHILD? WHY? Elizabeth Houshmand, MD reminisces about a very special summer vacation she took as a 6-year-old. Learn why it was so special and tops the list of her favorite childhood memories. PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably EXPLORING THE CONNECTION BETWEEN GUT HEALTH AND HAIR The Gut/Hair Connection. Evolving indicators suggest a connection between gut health and hair growth that remains to be proven. For example, when two refractory alopecia universalis patients underwent fecal-matter transplant (FMT) for recurrent Clostridium difficile infection (CDI), they experienced subsequent hair regrowth.This suggests gut flora composition may be associated with immune NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC Feature | October 2019 New Options for the Treatment of Extensive Seborrheic Keratosis A compounded formulation with an adhesive vehicle offers an alternative to OPTIMIZING ISOTRETINOIN TREATMENT: KEYS TO SUCCESSFULISOTRETINOIN PURGEWHAT TO EXPECT ON ACCUTANE Isotretinoin, the drug that revolutionized acne treatment, is the only medication that can clear acne and produce long-term remissions. Since its introduction in 1982, it continues to be a vital and widely used acne medication worldwide. TAKING THE PULSE OF HYDROQUINONE THERAPY: A PLEA FOR Feature | March 2013 Taking the Pulse of Hydroquinone Therapy: A Plea for Caution Pulse therapy under physician supervision can reduce long-term exposure and help reduce the risk of untoward effects of hydroquinone therapy. UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and TNF INHIBITORS AND THE RISK OF MELANOMA ONCOLOGY ATC AuGusT 2013 PRACTICAL DERMATOLOGY 47 Other studies have reached similar conclusions.7,8 However, the incidence of non-melanoma skin cancer has been NEW INSIGHTS INTO AZELAIC ACID CLINIC FOC ACNE/ROSACEA 46 PracTIcaL DErmaTOLOGY march 2013 improved for this indication, azelaic acid is commonly used off-label to treatpigmentation.
PRACTICAL DERMATOLOGYSUBSCRIBECURRENT ISSUEARCHIVEVIDEOSNEWSPODCASTS Practical Dermatology is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in medical and cosmetic dermatology. IN THE PIPELINE: WHAT TO KNOW ABOUT TAPINAROF Patients treated with tapinarof cream, 1% once daily demonstrated improvement in PASI 75 as early as week 2, according to data published in The Journal of the American Academy of Dermatology (JAAD) and reported by drug developer Dermavant. Data come from the Phase 2b randomized clinical trial of tapinarof, a therapeutic aryl hydrocarbon receptor modulating agent (TAMA), for the treatment of CHOOSE THE RIGHT CODES FOR SIMPLE, INTERMEDIATE, AND C PT lists several types of closures: simple, intermediate, complex, adjacent tissue transfer, and graft. The linear repairs—simple, inter-mediate, and complex—are probably EXPLORING THE CONNECTION BETWEEN GUT HEALTH AND HAIR The Gut/Hair Connection. Evolving indicators suggest a connection between gut health and hair growth that remains to be proven. For example, when two refractory alopecia universalis patients underwent fecal-matter transplant (FMT) for recurrent Clostridium difficile infection (CDI), they experienced subsequent hair regrowth.This suggests gut flora composition may be associated with immune NEW OPTIONS FOR THE TREATMENT OF EXTENSIVE SEBORRHEIC Feature | October 2019 New Options for the Treatment of Extensive Seborrheic Keratosis A compounded formulation with an adhesive vehicle offers an alternative to OPTIMIZING ISOTRETINOIN TREATMENT: KEYS TO SUCCESSFULISOTRETINOIN PURGEWHAT TO EXPECT ON ACCUTANE Isotretinoin, the drug that revolutionized acne treatment, is the only medication that can clear acne and produce long-term remissions. Since its introduction in 1982, it continues to be a vital and widely used acne medication worldwide. TAKING THE PULSE OF HYDROQUINONE THERAPY: A PLEA FOR Feature | March 2013 Taking the Pulse of Hydroquinone Therapy: A Plea for Caution Pulse therapy under physician supervision can reduce long-term exposure and help reduce the risk of untoward effects of hydroquinone therapy. UPDATE ON DIAGNOSIS AND TOPICAL MANAGEMENT OF ERYTHRASMA E rythrasma is a frequently under-diagnosed cutaneous infection caused by Corynebacterium minutissi-mum.It commonly affects body folds, particularly the groin, and TNF INHIBITORS AND THE RISK OF MELANOMA ONCOLOGY ATC AuGusT 2013 PRACTICAL DERMATOLOGY 47 Other studies have reached similar conclusions.7,8 However, the incidence of non-melanoma skin cancer has been NEW INSIGHTS INTO AZELAIC ACID CLINIC FOC ACNE/ROSACEA 46 PracTIcaL DErmaTOLOGY march 2013 improved for this indication, azelaic acid is commonly used off-label to treatpigmentation.
NEW RESEARCH SHOWS HOW IMMUNE CELLS ORGANIZE THEMSELVES IN New research reveals how the skin’s immune cells organize themselves to ward off would-be intruders. Skin’s immune cells have a history of being misunderstood. SKINSAFE, CVS NAME TOP 25 2021 SUNSCREEN AWARD WINNERS FOR June 7, 2021 SkinSAFE, CVS Name Top 25 2021 Sunscreen Award Winners for Sensitive Skin Developed in collaboration with Mayo Clinic, SkinSAFE helps people with sensitive skin find products that meet their sensitive skin needs, and to avoid products that may contain potential irritants. SKIN OF COLOR UPDATE GOES VIRTUAL FOR 2020 Skin of Color Update’s 2020 event is going virtual. The largest medical education event focused on the dermatologic treatment of skin of color will be held September 12-13. DIET AND INFLAMMATION IN DERMATOLOGY Preventing glycation in the skin is achieved by avoiding cooking with high heat and instead stewing, poaching, boiling, and steaming. Cooking with acids, such NPF COVID-19 TASK FORCE: MASKS, SOCIAL DISTANCING STILL NPF recommends that patients with psoriatic disease taking abatacept, cyclosporine, leflunomide, glucocorticoids (e.g., prednisone), methotrexate, or tofacitinib continue masking and social distancing precautions when they are in contact with people not UPDATE ON TB SCREENING PRIOR TO AND DURING BIOLOGIC The incidence of TB varies worldwide, with the highest cases of TB in the regions of South-East Asia (44 percent), Africa (24 percent), and the Western Pacific (18 percent), with smaller percentages in the Eastern Mediterranean (eight percent), the Americas (three percent), and Europe (three percent). DERMAVANT SUBMITS NDA FOR TAPINAROF FOR PSO Dermavant Sciences has submitted a New Drug Application (NDA) to the FDA for tapinarof for the treatment of mild, moderate, and severeplaque psoriasi
CAN BLOCKING THE FUNCTION OF THE CCR6 CHEMOKINE HELP TREAT June 4, 2021 Can Blocking the Function of the CCR6 Chemokine Help Treat Psoriasis and Psoriatic Arthritis? The researchers assessed the role of CCR6 and its binding partner CC chemokine ligand 20 (CCL20) in inflammation linked to psoriatic arthritis and psoriasis in a mousemodel.
THE PA SALARY: STRUCTURES AND STRATEGIES August 2012 The PA Salary: Structures and Strategies Just as there is a wide range of practice settings that utilize a PA, there is an array of salary structures for PAs. WHAT WAS YOUR FAVORITE TRIP AS A CHILD? WHY? Elizabeth Houshmand, MD reminisces about a very special summer vacation she took as a 6-year-old. Learn why it was so special and tops the list of her favorite childhood memories. PD-Mobile-Logo Created with Sketch.* Current Issue
* Archive
* Videos
* News
* Podcasts
*
More
downarrow Created with Sketch.* About
* Submissions
* Subscribe
* Events
* Topics
search Created with Sketch. search Created with Sketch. search Created with Sketch.* Current Issue
* Archive
* Videos
* News
* Podcasts
*
Topics
downarrow Created with Sketch.* Acne
* Cosmetic
* Eczema
* Infections
* Pediatric
* Practice Management* Psoriasis
* Residents
* Rosacea
* Skin Cancer
* Skin of Color
* About
* Submissions
* Subscribe
* Events
TOPICS:
Acne
Cosmetic
Eczema
Infections
Pediatric
Practice Management
Psoriasis
Residents
Rosacea
Skin Cancer
Skin of Color
Advertisement
Featured
CONVERSATIONS IN ACNE, PART 1 Neal Bhatia, MD, FAAD; James Q. Del Rosso, DO; and Hilary Baldwin, MDWatch Video
“NO-TOUCH” SURGICAL EXCISION & “DOUBLE-FREEZE-THAW” CRYOTHERAPY TECHNIQUES Antonio Yaghy, MD; Megan Ruben; Anoushka Gidh; and Carol L. Shields,MD
Watch Video
DERMWIRETV: AIRE SKINSTORE, TELEHEALTH CUTS CONSULT WAIT TIMES, SOCIAL MEDIA AND REALISTIC EXPECTATIONSWatch Video
KEEPING SEO A PRIORITY WHEN MANAGING YOUR BUDGET DURING COVIDEkwa Marketing
Watch Video
CONVERSATIONS IN ACNE, PART 2 Neal Bhatia, MD, FAAD; James Q. Del Rosso, DO; and Hilary Baldwin, MDWatch Video
DERMWIRETV: DOXIMITY PHYSICIAN COMPENSATION REPORT, EADV UPDATES, PSOIN THE KNOW
Watch Video
DERMWIRETV: SANOFI GENZYME & REGENERON GLOBAL AD REPORT; HYDROQUINONE;PFIZER NDA; VCS
Watch Video
LOOK TO THE EAST: SHARED DECISION MAKING IN THE ERA OF NEW THERAPIES Assessing Efficacy, Accessibility, Safety, and Tolerability is the key to a meaningful dialogue with patients. Peter Lio, MD, and Sean Rangwani Atopic dermatitis (AD) is a chronic, heterogeneous dermatosis with complex pathophysiology that comprises a deficient skin barrier, immune dysfunction, and dysbiosis, and affects up to 20 percent of children and three percent of adults.1,2 While there has been a nearly incredible revolution in the treatment of psoriasis, AD has been relatively left behind, until very recently.3,4 As our therapeutic armamentarium continues to expand, we are increasingly put in the position of selecting the best treatment for a given patient, and often have to choose between similar medications. Twenty years ago, choosing a systemic therapy for psoriasis was essentially limited to methotrexate and cyclosporine. Thus, it was fairly easy to choose, as the two drugs arguably have similar efficacy, but very different risks.5 For example, methotrexate is a teratogen and can cause hepatotoxicity, while cyclosporine has renal toxicity and adverse interactions with various other drugs, including statins.6,7 However, with the advent of biologic therapies, we now have an entire class of medications that, compared to conventional immunosuppressants, are generally both safer and more effective than these older agents. Indeed, in the past several years, we have witnessed an embarrassment of riches in psoriasis with each new drug, progressing from TNF-alpha inhibitors to IL-23 and IL-17 inhibitors, seemingly providing additional benefits over the last.8 The introduction of biosimilars into the market further expands the repertoire of psoriasis medications, making the decisions even more complicated. In AD, the long therapeutic drought is finally coming to an end with the advent of new biologic agents, topicals, and small molecules (Table 1). Thus, as in psoriasis and other areas of medicine with multiple treatment options, we will face increasing pressure to select intelligently. Selecting Intelligently How to decide appropriate treatment? The American Academy of Dermatology (AAD) and the Joint Task Force in Allergy are two of a number of groups that provide a set of clinical guidelines for AD, but the guidelines are not updated with the constantly evolving medications for AD, including biologics and Janus kinase (JAK) inhibitors.9,10 For mild to moderate AD, the AAD recommends initial non-pharmacological therapy, stressing patient education about using moisturizers and lifestyle modifications including altering bathing practices and avoiding potential allergens and triggers by being more cognizant of diet and environment.9 In addition, topical corticosteroids, topical calcineurin inhibitors, topical antimicrobials, antiseptics, and phototherapy may be used, as well.9,11 However, in moderate to severe cases, which represent about one-third of children and one-half of adults with AD, systemic therapy may be required, as lifestyle modifications, topical treatments, and phototherapy may not sufficiently control the disease.11–13 In addition to phototherapy and the often frowned-upon use of oral or intramuscular corticosteroids, systemic treatment for AD consists of the conventional immunosuppressive agents not approved for AD in the United States (i.e., cyclosporine, methotrexate, azathioprine, and mycophenolate mofetil), and a newer agent, dupilumab, a monoclonal antibody (mAb) that targets the IL-4/IL-13 pathway, initially approved in 2017.14–16 Over the past few years, there has been a tremendous increase in topical and systemic medications that have been approved or are in the pipeline for AD (Table 1). The AAD, in collaboration with the Choosing Wisely campaign, recommends against the use of systemic oral antibiotics unless there is a clear sign of infection and avoids using oral or injected systemic steroids for long-term treatment, due to the significant side effects.17 Additionally, Drucker et al recently published a systematic review with meta-analysis evaluating the relative effectiveness and safety of systemic medications for moderate-to-severe AD. The authors’ analysis of 20 medications mostly included studies comparing a drug to placebo, and only a few comparing different doses of the same drug, or comparing one drug to another drug in a head-to-head fashion. Nonetheless, the authors found that compared to methotrexate and azathioprine, dupilumab, and higher-dose cyclosporine were more effective in the first 16-weeks of treatment at improving clinical symptoms and quality of life. Furthermore, pipeline JAK inhibitors upadacitinib and abrocitinib showed promise as they had clinical outcomes comparable to dupilumab.18 Another systematic review by Alexander and colleagues that compared systemic therapies for AD found that dupilumab and nemolizumab, a monoclonal antibody against the IL-31 receptor, were superior to other treatments in terms of long-term control of AD.4 Beyond the general guidelines, and more complex than the question of which agent is simply “better,” there is a more nuanced matrix that can help differentiate therapies when deciding on course of action for an individual. Ideally, there is a shared decision-making process for each patient. When comparing different medications for AD, it may be beneficial to consider four characteristics: Efficacy (onset and maximum effect), Accessibility, Safety, and Tolerability, or EAST. Efficacy In some ways this is the central question about a medicine: Will it be effective for the patient’s problem? There are many dimensions to this, including the facts that most drugs elicit a range of effects, and individual responses may vary. However, there is a gestalt for most familiar medications that can be gleaned from both experimental data and clinical experience, and, broadly speaking, it can be broken down into two useful aspects: how quickly the medication begins to work and the magnitude of the maximal effect. For example, oral prednisone is fast acting and has a high maximal effect.19 On the other hand, mycophenolate mofetil, a B- and T-cell inhibitor that is also used in severe AD cases, has a much slower onset and lower maximal effect than does prednisone.20 Accessibility While the cost of the drug is important, this is a concept fraught with difficulty in American medicine. There is often an enormous disconnect between a listed cost and what the patient will actually pay for a medication, due to the myriad of players involved. Thus, a more practical concept is accessibility. Continuing our example of prednisone and mycophenolate mofetil, both drugs are fairly accessible. According to GoodRx.com, a popular tool used for drug pricing information, even without insurance coverage, a typical prescribed dose of prednisone (40 x 10mg tablets) costs less than $10, while mycophenolate mofetil (60 x 500mg tablets) costs less than $24, and both drugs are part of Medicare and Medicaid forumularies.21 Paradoxically, newer branded medications like crisaborole, despite being much more expensive than older generic drugs, can often be more accessible due to specialty pharmacies, manufacturers’ incentives, and coupons.22 The rapid changes in drug pricing, regional differences, and the impact of an individual’s insurance makes this attribute highly individualized for each patient. Safety Safety can be the deal-breaker for many drugs. Systemic steroids like prednisone have a large and serious side effect profile, which includes but is not limited to: diabetes, weight gain, Cushing syndrome, behavioral changes, sleep disturbances, adrenal insufficiency, hypertension, cataracts, glaucoma, and avascular necrosis. Thus, the use of systemic corticosteroids is best avoided or limited to the short-term when possible.14,19 Mycophenolate, on the other hand, has a more favorable safety profile, especially when comparing medium and even long-term use. Mycophenolate’s most common side-effects include nausea, vomiting, diarrhea, and other gastrointestinal disturbances.23 Some of the safety issues will apply broadly, while others may be especially relevant to select patients. A patient with pre-existing diabetes, for example, would be particularly ill-suited for systemic prednisone, particularly when other options are available; likewise, cyclosporine would be contraindicated in a patient with renal impairment. Tolerability Tolerability is often lumped together with safety, but it warrants classification as a unique parameter. Issues like “injection site pain” or “stinging and/or burning with application” are not true safety issues, but nonetheless can have an outsized effect on adherence and the overall patient experience. A powerful modern example is the topical ointment crisaborole. Crisaborole has a relatively favorable safety profile when compared to topical corticosteroids but has been noted to cause application site pain in four to 31 percent of patients, which certainly affects tolerability.24,25 All side effects, no matter their severity, have the potential to decrease patient adherence or even prevent initiation of treatment altogether. However, more nuanced understanding should enhance the shared decision making process. A Practical Approach While no absolute numbers exist for these parameters, each clinician can develop an individualized conception of these elements for treatments that should be considered. A helpful tool to visually compare medications is a Radar Chart. A blank Radar Chart with the arbitrary scale of 0-100 is included (Figure 1A). In figure 1B we have provided an example using a personal conceptualization of prednisone versus mycophenolate for AD. Again, it is important to note that different clinicians may have different impressions for these parameters, but working through them, and ideally sharing such a comparison with the patient, may be a helpful exercise to guide the discussion to a treatment decision, especially as new medications are added to the armamentarium. Figure 1. A: Blank Radar Chart. B: Radar Chart comparing prednisone (red) and mycophenolate (blue). 1. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: Section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-351. doi:https://doi.org/10.1016/j.jaad.2013.10.010 2. Nutten S. Atopic Dermatitis: Global Epidemiology and Risk Factors. Ann Nutr Metab. 2015;66(suppl 1(Suppl. 1):8-16. doi:10.1159/000370220 3. Noda S, Krueger JG, Guttman-Yassky E. The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol. 2015;135(2):324-336. doi:https://doi.org/10.1016/j.jaci.2014.11.015 4. Alexander H, Patton T, Jabbar-Lopez ZK, Manca A, Flohr C. Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution? . F1000Research. 2019;8(132). doi:10.12688/f1000research.17039.1 5. Heydendael VMR, Spuls PI, Opmeer BC, et al. Methotrexate versus Cyclosporine in Moderate-to-Severe Chronic Plaque Psoriasis. N Engl J Med. 2003;349(7):658-665. doi:10.1056/NEJMoa021359 6. Lebwohl M. A clinician’s paradigm in the treatment of psoriasis. J Am Acad Dermatol. 2005;53(1 SUPPL.):59-69. doi:10.1016/j.jaad.2005.04.031 7. Wiggins BS, Saseen JJ, Page RL, et al. Recommendations for Management of Clinically Significant Drug-Drug Interactions with Statins and Select Agents Used in Patients with Cardiovascular Disease: A Scientific Statement from the American Heart Association. Circulation. 2016;134(21):e468-e495. doi:10.1161/CIR.0000000000000456 8. Sakkas LI, Zafiriou E, Bogdanos DP. Mini review: New treatments in psoriatic arthritis. Focus on the IL-23/17 Axis. Front Pharmacol. 2019;10(JULY):1-8. doi:10.3389/fphar.2019.00872 9. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. doi:https://doi.org/10.1016/j.jaad.2014.03.023 10. Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: A practice parameter update 2012. J Allergy Clin Immunol. 2013;131(2):295-299.e27. doi:https://doi.org/10.1016/j.jaci.2012.12.672 11. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: Section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327-349. doi:https://doi.org/10.1016/j.jaad.2014.03.030 12. Silverberg JI, Simpson EL. Associations of childhood eczema severity: A US population-based study. Dermatitis. 2014;25(3):107-114. doi:10.1097/DER.0000000000000034 13. Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy Eur J Allergy Clin Immunol. 2018;73(6):1284-1293. doi:10.1111/all.13401 14. Drucker AM, Eyerich K, de Bruin-Weller MS, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. Br J Dermatol. 2018;178(3):768-775. doi:10.1111/bjd.15928 15. Megna M, Napolitano M, Patruno C, et al. Systemic Treatment of Adult Atopic Dermatitis: A Review. Dermatol Ther (Heidelb). 2017;7(1):1-23. doi:10.1007/s13555-016-0170-1 16. Paller AS, Kabashima K, Bieber T. Therapeutic pipeline for atopic dermatitis: End of the drought? J Allergy Clin Immunol. 2017;140(3):633-643. doi:10.1016/j.jaci.2017.07.006 17. Dermatology AA of. American Academy of Dermatology Ten Things Physicians and Patients Should Question. Choos Wisely, An Initiat ABIM Found. 2014;2013:10-11. 18. Drucker AM, Ellis AG, Bohdanowicz M, et al. Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis: A Systematic Review and Network Meta-analysis. JAMA Dermatology. 2020;156(6):659-667. doi:10.1001/jamadermatol.2020.0796 19. Yu SH, Drucker AM, Lebwohl M, Silverberg JI. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2018;78(4):733-740.e11. doi:https://doi.org/10.1016/j.jaad.2017.09.074 20. Grundmann-Kollmann M, Podda M, Ochsendorf F, Boehncke W-H, Kaufmann R, Zollner TM. Mycophenolate Mofetil Is Effective in the Treatment of Atopic Dermatitis. Arch Dermatol. 2001;137(7):870-873. doi:10-1001/pubs.Arch Dermatol.-ISSN-0003-987x-137-7-dst10044 21. Prescription Prices. Coupons & Pharmacy Information - GoodRx. 22. Lio P, Dover J, Mariwalla K. The Business of Dermatology. 23. Neuber K, Schwartz I, Itschert G, Dieck A to. Treatment of atopic eczema with oral mycophenolate mofetil. Br J Dermatol. 2000;143(2):385-391. doi:10.1046/j.1365-2133.2000.03667.x 24. Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. J Am Acad Dermatol. 2016;75(3):494-503.e6. doi:https://doi.org/10.1016/j.jaad.2016.05.046 25. Pao-Ling Lin C, Gordon S, Her MJ, Rosmarin D. A retrospective study: Application site pain with the use of crisaborole, a topical phosphodiesterase 4 inhibitor. J Am Acad Dermatol. 2019;80(5):1451-1453. doi:https://doi.org/10.1016/j.jaad.2018.10.054Read Article
SCIENTIFICALLY SPEAKING: CAN WE CONQUER CELLULITE? Joel L. Cohen, MD; Nazanin Saedi, MD; Michael P. McLane, PhD; andWally Klemp
Watch Video
*
*
*
*
*
*
*
*
*
VIDEO | NOVEMBER 2020 DERMWIRETV: AIRE SKINSTORE, TELEHEALTH CUTS CONSULT WAIT TIMES, SOCIAL MEDIA AND REALISTIC EXPECTATIONS VIDEO | NOVEMBER 2020 KEEPING SEO A PRIORITY WHEN MANAGING YOUR BUDGET DURING COVID VIDEO | NOVEMBER 2020 SCIENTIFICALLY SPEAKING: CAN WE CONQUER CELLULITE? VIDEO | NOVEMBER 2020 CONVERSATIONS IN ACNE, PART 2 VIDEO | NOVEMBER 2020 DERMWIRETV: DOXIMITY PHYSICIAN COMPENSATION REPORT, EADV UPDATES, PSOIN THE KNOW
VIDEO | OCTOBER 2020 DERMWIRETV: SANOFI GENZYME & REGENERON GLOBAL AD REPORT; HYDROQUINONE;PFIZER NDA; VCS
FEATURES |
OCTOBER 2020
LOOK TO THE EAST: SHARED DECISION MAKING IN THE ERA OF NEW THERAPIES RESIDENT RESOURCE CENTER|
OCTOBER 2020
“NO-TOUCH” SURGICAL EXCISION & “DOUBLE-FREEZE-THAW” CRYOTHERAPY TECHNIQUESRECENT NEWS
November 23, 2020
Merz Aesthetics Calls for Entries for First-Ever Innovation ForumNovember 23, 2020
Actress Zosia Mamet Named New Face of IsdinNovember 23, 2020
Study: Iron Oxides Offer Protection Skin from Blue LightNovember 19, 2020
Online Booking Functionality Comes to DemandforceNovember 18, 2020
Crown Aesthetics Scores Class IIa CE Certification for SkinPen Precision from British Standards InstitutionNovember 18, 2020
UCB, Stanford Medicine Partner to Seek New Ways to Treat HS, OtherDiseases
November 17, 2020
Research Identifies Long-Term Benefits of Incorporating Ceramides intoBaby Skincare
November 17, 2020
AAD Names Drs. Daval Bhanusali and Cory Maughan Patient Care Heroes for Treating Young Dog Bite VictimNovember 17, 2020
AAD Names Dr. Sacharitha Bowers a Patient Care Hero for Helping Address Disparities in Care Due to COVID-19November 17, 2020
Telemedicine Slashes Dermatology Consult Time from 84 Days to 5 HoursMore News
Advertisement
THE LATEST
Acne
Cosmetic
Eczema
Infections
Pediatric
Practice Management
Psoriasis
Residents
Rosacea
Skin Cancer
Skin of Color
VIEW MORE +
NEWS | NOVEMBER 23, 2020 Merz Aesthetics Calls for Entries for First-Ever Innovation Forum NEWS | NOVEMBER 23, 2020 Actress Zosia Mamet Named New Face of Isdin NEWS | NOVEMBER 23, 2020 Study: Iron Oxides Offer Protection Skin from Blue Light VIDEO | NOVEMBER 20, 2020 WHAT'S THE LAST SHOW YOU BINGE-WATCHED?PD Asks
Nazanin Saedi, MD tells us which show made her laugh and how she can't wait for the next season!Nazanin Saedi, MD
subscribe Created with Sketch.Subscribe
calendar Created with Sketch.Events
CME Created with Sketch.CME
Advertisement
SPONSORED VIDEO | NOVEMBER 19, 2020 LONG-TERM EFFICACY AND SAFETY DATA FROM ILUMYA™ CLINICAL TRIALSIlumya
Explore efficacy and safety data for ILUMYA™ from the reSURFACE 1 and reSURFACE 2 Phase 3 trials and extension studies. NEWS | NOVEMBER 19, 2020 Online Booking Functionality Comes to Demandforce VIDEO | NOVEMBER 18, 2020 DermWireTV: AIRE SkinStore, Telehealth Cuts Consult Wait Times, Social Media and Realistic ExpectationsDermWire TV
NEWS | NOVEMBER 18, 2020 Crown Aesthetics Scores Class IIa CE Certification for SkinPen Precision from British Standards Institution NEWS | NOVEMBER 18, 2020 UCB, Stanford Medicine Partner to Seek New Ways to Treat HS, OtherDiseases
NEWS | NOVEMBER 17, 2020 Research Identifies Long-Term Benefits of Incorporating Ceramides intoBaby Skincare
NEWS | NOVEMBER 17, 2020 AAD Names Drs. Daval Bhanusali and Cory Maughan Patient Care Heroes for Treating Young Dog Bite Victim NEWS | NOVEMBER 17, 2020 AAD Names Dr. Sacharitha Bowers a Patient Care Hero for Helping Address Disparities in Care Due to COVID-19 NEWS | NOVEMBER 17, 2020 Telemedicine Slashes Dermatology Consult Time from 84 Days to 5 Hours VIDEO | NOVEMBER 13, 2020 KEEPING SEO A PRIORITY WHEN MANAGING YOUR BUDGET DURING COVID With rising expenses and shrinking budgets, many dermatology practices are putting SEO on pause. Is that a wise move? Watch the latestvideo...
Ekwa Marketing
VIDEO | NOVEMBER 13, 2020 SCIENTIFICALLY SPEAKING: CAN WE CONQUER CELLULITE? Scientifically Speaking Treating cellulite has been a challenge, but new and emerging technologies offer hope to overcome this common condition. Host Joel L. Cohen, MD talks... Joel L. Cohen, MD; Nazanin Saedi, MD; Michael P. McLane, PhD; andWally Klemp
NEWS | NOVEMBER 12, 2020 Avita Therapeutics, Houston Methodist Research Institute to Develop New Ways to Rejuvenate Aging Skin NEWS | NOVEMBER 11, 2020 More Positive Phase 3 Data for Pfizer's Abrocitinib in AD SPONSORED VIDEO | NOVEMBER 11, 2020 SEE HOW ILUMYA™ WORKSIlumya
Learn about the immunopathogenesis of plaque psoriasis, and how the IL-23 inhibitor ILUMYA™ controls the release of key cytokines to... NEWS | NOVEMBER 10, 2020 Verrica's VP-102 has Positive Results in Phase 2 EWG Trial NEWS | NOVEMBER 10, 2020 Bristol Myers Squibb's Deucravacitinib Performs Well in Phase 2 Study in Patients with Psoriatic ArthritisView more
MODERN AESTHETIC SERIES Experts tackle issues that matter to dermatologists, plastic surgeons, and other aesthetic specialists during the COVID-19 crisis.View Series
BREAKING NEWS
Get updates on the impact of COVID-19 from _Practical Dermatology_®View News
STAY UP TO DATE
Stay up to date on all things Dermatology by signing up to recieve our print publication or subscribe to our email alerts. email-new Created with Sketch. Sign Up INTERESTED IN AESTHETICS? Check out Modern Aesthetics®, our sister publication to see the latest expert advice and innovations in aesthetics. Visit Modern AestheticsAdvertisement
EVENTS
View More Events
FEATURED VIDEO SERIESSponsored
Sponsored
MakingConnections-WebinarGroup 35
Sponsored
dermwire-tv-logo Created with Sketch.Sponsored
Sponsored
ask-an-expert Created with Sketch.View More +
MEETING COVERAGE
IMCASWorldCongress2019 Created with Sketch. aad2019-summer-logo Created with Sketch. AADAnnualMeeting2019 Created with Sketch.View More +
TOPICS:
Acne
Cosmetic
Eczema
Infections
Pediatric
Practice Management
Psoriasis
Residents
Rosacea
Skin Cancer
Skin of Color
* Current Issue
* Archive
* Dermtube Videos
* Dermwire News
* Topics
* About
* Submissions
* Subscribe
* Events
* Contact
Practical Dermatology® is a publication dedicated to providing the latest developments in medical and cosmetic dermatology. twitter Created with Sketch. facebook Created with Sketch. twitter Created with Sketch. linkedin Created withSketch.
book Created with Sketch. Start Your Free Print Subscription Today email-new Created with Sketch. Stay Updated:Subscribe to our E-blasts PD-BMC-Group Created with Sketch. 2020 Bryn Mawr Communications III, LLC. All RIghts Reserved •Privacy Policy
onetrust-logo Created with Sketch.*
Your Privacy
*
Strictly Necessary Cookies*
Performance Cookies
*
Targeting Cookies
*
More Information
PRIVACY PREFERENCE CENTREActive
Always Active
Save Settings
Allow All
We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analyticspartners.
Close
Accept Cookies
Cookie Settings
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0